Market revenue in 2023 | USD 1.6 million |
Market revenue in 2030 | USD 5.5 million |
Growth rate | 18.9% (CAGR from 2023 to 2030) |
Largest segment | Pure prp |
Fastest growing segment | Leukocyte Rich PRP |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pure PRP, Leukocyte Rich PRP |
Key market players worldwide | Johnson & Johnson, Arthrex, Terumo Corp, Zimmer Biomet Holdings Inc, Stryker Corp, EmCyte Corporation, Dr. PRP USA, Juventix Regenerative Medical, APEX Biologix, Celling Biosciences |
Pure prp was the largest segment with a revenue share of 50% in 2023. Horizon Databook has segmented the UAE platelet rich plasma (prp) market based on pure prp, leukocyte rich prp covering the revenue growth of each sub-segment from 2018 to 2030.
Arthritis has a significant impact on the Middle Eastern population, affecting individuals across all age groups. Although there are no specific statistics for the UAE, data from the Gulf region indicates that arthritis prevalence is around 20% of the population.
In Dubai, where healthcare advancements are prioritized, innovative treatments such as PRP therapy play a crucial role in managing and alleviating arthritis-related symptoms. PRP offers a promising avenue for individuals seeking nonsurgical and effective solutions to manage their arthritis, contributing to improved quality of life for many in the UAE facing these challenging conditions.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account